Sexual SatisfactionNCT06891547
Radicle Spark for Women™ 24: Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes
A study testing Spark Active Study Product 5.1 Usage in people with Sexual Satisfaction and Sexual Function, run by Radicle Science at 1 site in United States.
Trial summary
A randomized, double-blind, placebo-controlled, direct-to-consumer study assessing the impact of health and wellness products on sexual health and related health outcomes. Read more about this study
- Who is it for?
- Ages 21 to 105 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Sexual Satisfaction, Sexual Function
- What is being tested?
- Spark Active Study Product 5.1 Usage
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 600 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Feb 2025to 11 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 105 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities - Assigned sex at birth is female
- Resides in the United States
- Endorses improved libido (sex drive), sexual satisfaction and/or function as a primary desire
- Has the opportunity for at least 30% improvement in their primary health outcome
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Who cannot join
- Report being pregnant, trying to become pregnant, or breastfeeding
- Unable to provide a valid US shipping address and mobile phone number
- Reports current enrollment in another clinical trial
- Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
- Unable to read and understand English
- Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
Show all 12Show fewer
- Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
- o NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
- Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
- o Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
- Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products
- Lack of reliable daily access to the internet
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Radicle Spark for Women™ 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes
A randomized, double-blind, placebo-controlled, direct-to-consumer study assessing the impact of health and wellness products on sexual health and related health outcomes.
Read the detailed description
This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States. Eligible participants will (1) endorse a desire for improved libido (sex drive), sexual satisfaction and/or function, (2) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded. Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
- Conditions
- Sexual Satisfaction, Sexual Function
- Being tested
- Spark Placebo Control 5.1, Spark Active Study Product 5.1 Usage
- Medical subject headings
- Orgasm
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Spark Placebo Control 5.1Dietary supplement
Participants will use their Radicle Spark Placebo Product 5.1 as directed for a period of 6 weeks.
Spark Active Study Product 5.1 UsageDietary supplement
Participants will use their Radicle Spark Active Study Product 5.1 as directed for a period of 6 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Placebo Control 5.1.0 | Placebo comparator | Spark Product 5.1 - control Receives: Dietary Supplement: Spark Placebo Control 5.1 |
| Active Product 5.1.1 | Experimental | Spark Product 5.1 - active product 1 Receives: Dietary Supplement: Spark Active Study Product 5.1 Usage |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in sexual health
Mean difference in sexual health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Full Profile Sexual Function and Satisfaction Survey (Female) (where lower scores correspond to lower sexual function and satisfaction)
Measured: 6 weeks
Secondary outcomes (7)
Change in feelings of stress
Mean difference in feelings of stress score as assessed by Perceived Stress Scale 4 (PSS-4) (scale 0-16; where lower scores correspond to less stress)
Measured: 6 weeks
Change in fatigue
Mean difference in fatigue as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue)
Measured: 6 weeks
Change in mood (emotional distress-depression)
Mean difference in mood score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; where higher scores correspond to more severe emotional distress-depression)
Measured: 6 weeks
Minimal clinical importance difference (MCID) in sexual health
Likelihood of achieving a MCID in sexual health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Full Profile Sexual Function and Satisfaction Survey (Female) (where lower scores correspond to lower sexual function and satisfaction)
Measured: 6 weeks
Minimal clinical importance difference (MCID) in feelings of stress
Likelihood of achieving a MCID in feelings of stress score as assessed by Perceived Stress Scale 4 (PSS-4) (scale 0-16; where lower scores correspond to less stress)
Measured: 6 weeks
Minimal clinical importance difference (MCID) in fatigue
Likelihood of achieving a MCID in feelings of fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 4A (scale 4-20; where higher scores correspond to more severe fatigue)
Measured: 6 weeks
Minimal clinical importance difference (MCID) in mood (emotional distress-depression)
Likelihood of achieving a MCID in mood score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; where higher scores correspond to more severe emotional distress-depression)
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2025
- Study start20 Feb 2025
- Primary completion4 Aug 2025
- Study completion11 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sexual SatisfactionStudies of the same condition, open and under way.
- More trials run by Radicle ScienceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be stratified based on their age and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 600 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radicle Science
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06891547
- Sponsor's protocol ID
- RADX-P-2410
- Status last verified
- Aug 2025
- First submitted
- 17 Mar 2025
- Last updated
- 15 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will not be shared with researchers outside of Radicle Collaborators on this study.
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Radicle Spark for Women™ 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes
- ClinicalTrials.gov ID
- NCT06891547
- Acronym / sponsor ID
- RADX-P-2410
- Conditions
- Sexual Satisfaction, Sexual Function
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 600 participants (actual)
- Lead sponsor
- Radicle ScienceIndustry (pharma, biotech, devices)
- Study start
- 20 Feb 2025 (actual)
- Primary completion
- 4 Aug 2025 (actual)
- Study completion
- 11 Aug 2025 (actual)
- First posted
- 24 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A randomized, double-blind, placebo-controlled, direct-to-consumer study assessing the impact of health and wellness products on sexual health and related health outcomes.
Detailed description
This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States. Eligible participants will (1) endorse a desire for improved libido (sex drive), sexual satisfaction and/or function, (2) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded. Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Participants will be stratified based on their age and health outcome score during enrollment, then randomized to one of the study arms. Each participant will have an equal chance of being assigned to any study arm.
| Arm | Type | Receives |
|---|---|---|
| Placebo Control 5.1.0 | Placebo comparator | Dietary Supplement: Spark Placebo Control 5.1Spark Product 5.1 - control |
| Active Product 5.1.1 | Experimental | Dietary Supplement: Spark Active Study Product 5.1 UsageSpark Product 5.1 - active product 1 |
Who may qualify
- Ages
- 21 to 105 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities - Assigned sex at birth is female
- Resides in the United States
- Endorses improved libido (sex drive), sexual satisfaction and/or function as a primary desire
- Has the opportunity for at least 30% improvement in their primary health outcome
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Key exclusion criteria (12 listed)
- Report being pregnant, trying to become pregnant, or breastfeeding
- Unable to provide a valid US shipping address and mobile phone number
- Reports current enrollment in another clinical trial
- Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
- Unable to read and understand English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Spark Placebo Control 5.1Participants will use their Radicle Spark Placebo Product 5.1 as directed for a period of 6 weeks. | Dietary supplement | Placebo Control 5.1.0 |
| Spark Active Study Product 5.1 UsageParticipants will use their Radicle Spark Active Study Product 5.1 as directed for a period of 6 weeks. | Dietary supplement | Active Product 5.1.1 |
Primary outcome
Change in sexual health
Time frame: 6 weeks
Mean difference in sexual health score as assessed by Patient Reported Outcome Measurement System (PROMIS) Full Profile Sexual Function and Satisfaction Survey (Female) (where lower scores correspond to lower sexual function and satisfaction)
7 secondary outcomes
Change in feelings of stress
Time frame: 6 weeks
Change in fatigue
Time frame: 6 weeks
Change in mood (emotional distress-depression)
Time frame: 6 weeks
Minimal clinical importance difference (MCID) in sexual health
Time frame: 6 weeks
Minimal clinical importance difference (MCID) in feelings of stress
Time frame: 6 weeks
Minimal clinical importance difference (MCID) in fatigue
Time frame: 6 weeks
Minimal clinical importance difference (MCID) in mood (emotional distress-depression)
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2025.
- Radicle Science, IncLink provided by the sponsor.
- Individual participant dataSharing planned: No. Data will not be shared with researchers outside of Radicle Collaborators on this study.
Related trials for Sexual Satisfaction
Not yet recruiting
Genital Self İmage and Satisfaction With Genital Appearance
Women
Active, not recruiting
Reducing Stigma and Building Employability Skills for Young People With HIV in Zambia
HIV, Mental Health
Enrolling by invitation
Intervention to Reduce HIV Related Stigma Among Pregnant and Postpartum Women
HIV, HIV - Human Immunodeficiency Virus
Not yet recruiting
A Clinical Trial to Evaluate the Effects of the NeuEve Dryness Treatment Kit on Vaginal Health, Comfort, and Quality of Life in Postmenopausal Women
Relieves Vaginal Dryness / Improves Self-Lubrication, Improves Strength & Elasticity of Vagina (Aka Collagen and Elastin)
Enrolling by invitationObservational study
HoLEP Sexual Survivorship
BPH, Lower Urinary Tract Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Spark Active Study Product 5.1 Usage in people with Sexual Satisfaction and Sexual Function, run by Radicle Science at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in sexual health (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2025.